NCT06891755招募中不适用
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Apreo Health, Inc.32 个研究点 分布在 4 个国家目标入组 250 人开始时间: 2025年7月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 250
- 试验地点
- 32
- 主要终点
- Forced Expiratory Volume in 1 second (FEV1) Responder
研究概览
简要总结
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The main questions it aims to answer are: Is it safe? Does it work?
详细描述
Prospective, randomized, two arm, parallel group, concurrently controlled, open-label, multi-center clinical trial following up to 250 participants to 3 years.
Each site will participate in a Roll-In phase prior to participation in the randomized phase of the study. Each site will enroll up to 2 subjects in this phase. Up to 50 subjects may be enrolled into the Roll-In cohort.
Up to 200 subjects with bilateral emphysema will be randomized at up to 25 centers in the United States centers and Europe.
In the Randomized cohort, subjects will be randomized to either a Treatment or Control group in a 2:1 ratio.
- Optimal Medical Management: All subjects (Roll-in and Randomized) will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.
- Treatment group: 133 subjects will receive optimal medical management and Apreo Implant placements. Treatment group subjects will undergo a single bronchoscopy with bilateral placement of up to 3 implants per lung in appropriately selected target airways. Appropriate target segments shall be based on segmental and lobar information (i.e. airway dimensional, emphysematous destruction, volumetric information, hetero/homogeneity) provided in the Quantitative CT (QCT) report for each patient.
- Control group: 67 subjects will receive optimal medical management. Control group subjects will be allowed the opportunity to cross over and receive the BREATHE treatment after their Month 12 visit and within 15 months from their baseline visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria
- •Subject is at least 40, but not older than 84, years of age.
- •Subject has body mass index (BMI) of between 18 and 32, inclusive.
- •Subject has completed a documented pulmonary rehabilitation program within 12 months prior to Baseline.
- •Subject has mMRC score ≥
- •Subject can walk ≥100 meters in 6 minutes.
- •Subject has ≥25% emphysema destruction score in each lung as quantified on baseline HRCT scan (low attenuation area less than -950HU) as determined by the CT core lab.
- •Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score (-910HU) as determined by the CT core lab.
- •Subject has bilateral heterogenous emphysema and pre-procedure post-bronchodilator RV ≥ 180% predicted, or one lung with homogenous emphysema and pre-procedure postbronchodilator RV ≥ 200% predicted.
- •Subject has pre-procedure post-bronchodilator FEV1/ FVC < 0.
- •Subject has a pre-procedure post-bronchodilator FEV1 percent predicted of ≥15% and ≤45%.
- •Subject has pre-procedure post-bronchodilator RV/TLC ≥ 0.
- •Subject has pre-procedure DLCO ≥ 20%.
- •Subject has been receiving optimal medical management tailored to subject needs for 2 months prior to enrollment.
- •Subject has not actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 4 months, and agrees to smoking cessation during the study.
- •Subject has received preventative vaccinations (or documented clinical intolerance) against potential respiratory infections, including pneumococcus, influenza, RSV (subjects >60 yrs. old) and Covid-19, consistent with local recommendations or policy.
- •In the opinion of the Primary investigator, subject can undergo bronchoscopy under general anesthesia and is able to adhere to the study follow-up schedule.
- •Subject has provided written informed consent.
排除标准
- •Subject has known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).
- •Subject has a steroid-dependent condition requiring (e.g. ≥10 mg oral corticosteroid per day).
- •Subject has bilateral lobar emphysematous destruction scores of >70% percent of voxels with <-950 Hounsfield units on thin slice inspiratory CT, as determined by the CT core lab.
- •Subject has arterial or capillary blood on room air: PaCO2 > 50 mmHg (8 kPa) or PaO2 ≤ 45 mmHg (6 kPa).
- •Subject has had ≥2 hospitalization for acute exacerbations of COPD or ≥3 moderate exacerbations/respiratory infections in the year prior to enrollment.
- •Subject has had previous lung volume reduction surgery, lobectomy, pneumonectomy, segmentectomy, bullectomy, lung transplantation, vapor, glue, or other pulmonary device implant (unless the device has been removed at least 3 months prior to consent).
- •Subject has known or suspected history of pulmonary arterial hypertension (e.g. PASP > 50mmHg on echocardiogram in absence of confirmation on a right heart catheterization or mPAP > 25mmHg on a right heart catheterization).
- •Subject has presence of a giant bulla (≥ 30% of hemithorax).
- •Subject has significant symptom burden due to currently active adult asthma based on GINA criteria and/or chronic bronchitis as their primary diagnosis.
- •Subject has presence of suspicious radiological abnormalities on HRCT scan such as pulmonary nodule/infiltrate that in judgement of the PI, may require intervention during course of the study.
- •Subject has clinically significant bronchiectasis (>4 TBS / 45mL mucus production/day, per subject estimate) influencing subject's COPD symptoms.
- •Subject has unresolved lung cancer.
- •Subject has a serious medical condition that, in the Primary investigator's opinion, could compromise patient safety or confound the interpretation of the patient's response to therapy (e.g., congestive heart failure, cardiomyopathy (documented LVEF ≤40%), or myocardial infarction in the past year, renal failure, liver disease cerebrovascular accident within the past 6 months, uncontrolled diabetes (HbA1c >8%), uncontrolled hypertension (diastolic BP >110 mmHg or systolic >200 mmHg) or autoimmune disease requiring treatment with immunosuppressant medications or a disease requiring chemotherapy.
- •Subject is on anticoagulant or antiplatelet therapy for cardiovascular indications and, at the discretion of the Primary investigator, is unable to have anticoagulants withheld for a bronchoscopy procedure per institution's standard of care.
- •Subject has invasive mechanical ventilator dependency.
- •Subject is pregnant, lactating, or of childbearing potential and plans to become pregnant during study duration.
- •Subject has known hypersensitivity to Nitinol (nickel-titanium alloy) or its constituent metals (nickel or titanium).
- •Subject is significantly immunocompromised, such as organ transplant recipients, those with congenital immune deficiencies, AIDS, or severe rheumatoid arthritis.
- •Subject has sensitivity or allergy to medications necessary for bronchoscopy under general anesthesia.
- •Subject is currently participating in another study involving an investigational product that could confound the study results or affect the subject's COPD symptoms.
- •Subject has within the 2 years prior to consent, had a severe respiratory infection with SARS-CoV-2 (COVID-19) that required ICU support with non-invasive and/or invasive mechanical ventilation.
研究组 & 干预措施
Apreo implants + Optimal Medical Management
Experimental
Treatment group participants will receive optimal medical management and will undergo a single bronchoscopy with bilateral placement of up to 3 implants per lung in appropriately selected targeted airways.
干预措施: Apreo BREATHE Airway Scaffold (Device)
Optimal Medical Management
Other
Control group participants will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.
干预措施: Optimal Medical Management (OMM) (Other)
结局指标
主要结局
Forced Expiratory Volume in 1 second (FEV1) Responder
时间窗: Month 12
Defined as a subject who experiences a reduction from baseline in post-bronchodilator FEV1 of ≥12%
次要结局
- 6-minute walk distance (6MWD)(Months 3, 6, 12 and Years 2, 3)
- Residual Volume (RV) + St George's Respiratory Questionnaire for COPD (SGRQ-C)(Months 3 and 12)
- COPD Assessment Test (CAT) Responder Rate(Months 3, 6, 12 and Years 2, 3)
- Forced Expiratory Volume in the first second (FEV1) Responder Rate(Months 3, 6, 12 and Years 2, 3)
- St. George's Respiratory Questionnaire for COPD (SGRQ-C) Responder Rate(Months 3, 6, 12 and Years 2, 3)
- Modified Medical Research Council (mMRC) Responder Rate(Months 3, 6, 12 and Years 2, 3)
- Ratio of residual volume (RV)/ total lung capacity (TLC) Responder Rate(Months 3, 6, 12 and Years 2, 3)
- Residual Volume (RV) Responder Rate(Months 3, 6, 12 and Years 2, 3)
- Forced Vital Capacity (FVC) Responder Rate(Months 3, 6, 12 and Years 2, 3)
研究者
研究点 (32)
Loading locations...
相似试验
招募中
不适用
Bronchoscopic Release of Air Trapped in Hyperinflated Emphysematous LungCOPD10038716emphysemaNL-OMON56894Medical Devices company - Apreo Health Inc.25
进行中（未招募）
不适用
avage Bronchiolo-Alvéolaire sous ventilation non Invasive et sédation intra veineuse en objectif de concentration au Propofol chez le malade en insuffisance Respiratoire Aiguë.Etude Randomisée Contrôlée - SEDA-FIBROPatient présentant une Insuffisance Respiratoire Aigüe avec nécessité d'une fibroscopie bronchique avec Lavage Bronchiolo-Alvéolaire.MedDRA version: 9.1Level: LLTClassification code 10001053Term: Acute respiratory failureEUCTR2008-000757-35-FRCHU de Bordeaux
已完成
不适用
Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane AnesthesiaAnesthesiaSurgeryNCT01151267University Health Network, Toronto44
招募中
不适用
Flexible Bronchoscopy Insufflated and High-Flow Nasal Oxygen Pilot Trial in ChildreACTRN12621001635853niversity of Queensland80
已完成
1 期
Bubble Continuous Positive Airway Pressure Oxygen Therapy in Children u with PneumoniaCTRI/2021/08/035409Biodesign Innovation Labss RESPAP KIT30